Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Therapeutic perspectives in multiple sclerosis].

Catherine Lubetzki1

  • 1Fédération des maladies du système nerveux, hopital La Salpêtrière, AP-HP, université Pierre et Marie Curie, 75651 Paris 13. catherine.lubetzki@psl.aphp.fr

La Revue Du Praticien
|September 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnetoencephalography biomarkers for assessing myelin content and neuronal function in acute optic neuritis.

Brain communications·2026
Same author

Neuronal Activity Promotes Node-Like Cluster Assembly Prior to Myelination and Remyelination in the Central Nervous System.

Glia·2026
Same author

Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder.

Neurology·2025
Same author

Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.

Frontiers in immunology·2024
Same author

Cerebellar encephalitis and peripheral neuropathy with an atypical clinical and neuroimaging signature following Covid-19 vaccine: a report of two cases.

Journal of neurology·2024
Same author

Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies.

Multiple sclerosis and related disorders·2024

Current multiple sclerosis treatments offer partial relief. Future therapies may combine anti-inflammatory drugs with myelin repair strategies for better outcomes in managing this central nervous system disease.

Area of Science:

  • Neuroimmunology
  • Regenerative Medicine

Context:

  • Multiple sclerosis (MS) treatments have improved, but current anti-inflammatory strategies show limited efficacy.
  • Existing therapies primarily target the inflammatory component of MS, leaving significant unmet needs.

Purpose:

  • To explore emerging therapeutic perspectives for multiple sclerosis.
  • To evaluate novel treatment strategies including immunomodulation, immunosuppression, immunotherapy, and tissue repair.

Summary:

  • Monoclonal antibodies inhibiting lymphocyte entry into the CNS are promising but require benefit/risk assessment.
  • Combination strategies involving immunomodulators, immunosuppressants, and specific immunotherapy are under investigation.
  • Longer-term experimental approaches focus on repairing axonal and myelin damage, currently in preclinical stages.

Related Experiment Videos

Impact:

  • Optimized MS therapy may involve combining upstream anti-inflammatory treatments with downstream neuroprotective and myelin repair strategies.
  • This integrated approach aims to address both immune response and tissue damage in MS lesions.
  • Future treatments hold the potential for more comprehensive management and improved patient outcomes in multiple sclerosis.